Dynamics of Changes in Chromogranin A Concentration as a Prognostic Factor Radiopeptide Therapy in Neuroendocrine Tumours Abstract #3055

Introduction: Chromogranin A (CgA) is a non-specific marker of neuroendocrine tumors (NET) and its significantly increased level is an unfavorable prognostic factor while the decrease in CgA during biotherapy with somatostatin analogs (SSA) correlates with the increase in profession free survival (PFS).
Aim(s): To evaluate the dynamics of CgA changes and its prognostic significance during treatment with radiolabelled somatostatin analogs (PRRT) in patients with G1/G2 NET.
Materials and methods: 91 patients, mean age 56, treated with PRRT were included. Radiolabelled with 90Y or 177Lu DOTATATE was delivered in 4 to 5 cycles at 6-12 weeks intervals. After completion of PRRT, patients were randomized to biotherapy with SSA or observation. Chromogranin A was evaluated before each treatment cycle, 6-12 weeks after treatment, and then during at 6-12 months. An increase or decrease of at least 25% was considered significant.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Daria Handkiewicz-Junak
Keywords: CgA, PRRT, prognosis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2849 PRRT Neuroendocrine Tumor Response Assessment Using Circulating Transcript Analysis: The NETest
Introduction: The absence of an accurate blood biomarker to predict and monitor PRRT is a key unmet need.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
#2842 Transformation to High Grade 3 (G3) Neuroendocrine Neoplasia (NEN) – Molecular Imaging, Pathologic Features and Patient Outcomes
Introduction: Transformation of lower grade to Grade 3 (G3) NEN potentially impacts prognosis & treatment options.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Grace Kong
Authors: Kong G, Callahan J, Prall O, Michael M, ...
#3001 Early Response Assessment for Prediction of Overall Survival after Peptide Receptor Radionuclide Therapy
Introduction: PRRT response assessment is performed using RECIST, yet functional assessment using 68Ga-DOTATATE PET/CT and plasma CgA might give additional information about prediction of overall survival (OS).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Daphne Huizing
#2734 Therapy-Related Myeloid Neoplasms in Patients with Neuroendocrine Neoplasms after Peptide Receptor Radionuclide Therapy: A Systematic Review
Introduction: Therapy-related myeloid neoplasm (t-MN) has been reported as a potential long-term and frequently lethal adverse event after PRRT in NET. However, the incidence, time of diagnosis, and nature of t-MN is unclear.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: DR Mohamad Sonbol
Authors: Sonbol M, Hilal T, Halfdanarson T, ...
#2937 Brain Metastasis in Patients with Neuroendocrine Neoplasia of Gastroenteropancreatic Origin: A Single Centre Experience
Introduction: Brain metastasis (BrMet) in patients (pts) with neuroendocrine neoplasia (NEN) of gastroenteropancreatic (GEP) origin is extremely rare. Data on management and outcome are limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Javad Saghebi
Authors: Saghebi J, Hicks R, Michael M, Kong G, ...